{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:55:58Z","timestamp":1787504158134,"version":"build-2736575974"},"reference-count":124,"publisher":"Bentham Science Publishers Ltd.","issue":"18","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diabetes, a metabolic disease occurs due to decrease or no effect of insulin on blood glucose level.\nCurrent oral medication stimulates insulin release, increase glucose absorption and its utilization as well decrease hepatic\nglucose output. Two major incretin hormones like Glucose dependent insulinotropic polypeptide (GIP) and glucagon like\npeptide \u2013 1 (GLP -1) stimulate insulin release after meal but their action is inhibited by enzyme dipeptidyl peptidase- IV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The activity of endogenous GLP-1 and GIP prolong and extend with DPP IV inhibitors which are responsible for\nstimulation of insulin secretion and regulate blood glucose level. DPP IV inhibitors have shown effectiveness and endurability with neutral effect on weight as well as less chances of hypoglycemia in management of type 2 diabetes. These journeys\nhave been started from Sitagliptin (marketed in 2006) to Evogliptin (marketed in 2015, Korea).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Treatment of type 2 diabetes includes lifestyle changes, oral medications, and insulin. Newer and superior\ntherapies are required than presently prescribed drugs. Various heterocyclic derivatives have been tried but due\nto masking of DASH proteins, CYP enzymes and hERG channel, they showed side effects. Based on these,\nstudy has been focused on the development of safe, influential, selective and long-lasting inhibitors of DPP IV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867327666201012153255","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T03:17:07Z","timestamp":1602559027000},"page":"3595-3621","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-7132","authenticated-orcid":true,"given":"Bhumi M.","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, K.B. Institute of Pharmaceutical Education and Research, Gandhinagar, Gujarat 382023,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-9029","authenticated-orcid":true,"given":"Palmi","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, L.J. Institutes of Pharmacy, Sarkhej, Ahmedabad, Gujarat 382210,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-6372","authenticated-orcid":true,"given":"Priti","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, K.B. Institute of Pharmaceutical Education and Research, Gandhinagar, Gujarat 382023,India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"IDF DIABETES ATLAS9th edition 2019. Available at:  (accessed on Dec 12th, 2018)."},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4066\/AMJ.2014.1979","volume":"7","author":"Kaveeshwar S.A.","year":"2014","unstructured":"Kaveeshwar S.A.; Cornwall J.; The current state of diabetes mellitus in India. Australas Med J 2014,7(1),45-48","journal-title":"Australas Med J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Zheng Y.","year":"2018","unstructured":"Zheng Y.; Ley S.H.; Hu F.B.; Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018,14(2),88-98","journal-title":"Nat Rev Endocrinol"},{"key":"ref=4","first-page":"509","volume":"35","author":"Pathak R.","year":"2010","unstructured":"Pathak R.; Bridgeman M.B.; Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P 2010,35(9),509-513","journal-title":"P"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1331\/JAPhA.2009.09078","volume":"49","author":"Neumiller J.J.","year":"2009","unstructured":"Neumiller J.J.; Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009,49((Suppl. 1)),S16-S29","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2337\/dc06-9912","volume":"29","author":"Nathan D.M.","year":"2006","unstructured":"Nathan D.M.; Buse J.B.; Davidson M.B.; Heine R.J.; Holman R.R.; Sherwin R.; Zinman B.; Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes association and the European association for the study of diabetes. Diabetes Care 2006,29(8),1963-1972","journal-title":"Diabetes Care"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","volume":"60","author":"Barnett A.","year":"2006","unstructured":"Barnett A.; DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006,60(11),1454-1470","journal-title":"Int J Clin Pract"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2174\/156802607780091019","volume":"7","author":"Sebokova E.","year":"2007","unstructured":"Sebokova E.; Christ A.D.; Boehringer M.; Mizrahi J.; Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr Top Med Chem 2007,7(6),547-555","journal-title":"Curr Top Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3132\/dvdr.2006.024","volume":"3","author":"Green B.D.","year":"2006","unstructured":"Green B.D.; Flatt P.R.; Bailey C.J.; Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006,3(3),159-165","journal-title":"Diab Vasc Dis Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00577838","volume":"7","author":"Hopsu-Havu V.K.","year":"1966","unstructured":"Hopsu-Havu V.K.; Glenner G.G.; A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-&#x3B2;-naphthylamide. Histochemie 1966,7(3),197-201","journal-title":"Histochemie"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/cei.12757","volume":"184","author":"Wagner L.","year":"2016","unstructured":"Wagner L.; Klemann C.; Stephan M.; von H&#xF6;rsten S.; Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and\/or structure homologue (DASH) proteins. Clin Exp Immunol 2016,184(3),265-283","journal-title":"Clin Exp Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00125-014-3299-4","volume":"57","author":"Omar B.A.","year":"2014","unstructured":"Omar B.A.; Liehua L.; Yamada Y.; Seino Y.; Marchetti P.; Ahr&#xE9;n B.; Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 2014,57(9),1876-1883","journal-title":"Diabetologia"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"Mulvihill E.E.","year":"2014","unstructured":"Mulvihill E.E.; Drucker D.J.; Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 2014,35(6),992-1019","journal-title":"Endocr Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"Thomas L.","year":"2008","unstructured":"Thomas L.; Eckhardt M.; Langkopf E.; Tadayyon M.; Himmelsbach F.; Mark M.; (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008,325(1),175-182","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","volume":"13","author":"Deacon C.F.","year":"2011","unstructured":"Deacon C.F.; Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011,13(1),7-18","journal-title":"Diabetes Obes Metab"},{"key":"ref=16","unstructured":"DiaTribe Learn, making sense of diabetes. DPP-4 inhibitors. Available at:  (accessed on Januray 12th, 2019)."},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1016\/j.bmcl.2005.08.050","volume":"15","author":"Haffner C.D.","year":"2005","unstructured":"Haffner C.D.; McDougald D.L.; Reister S.M.; Thompson B.D.; Conlee C.; Fang J.; Bass J.; Lenhard J.M.; Croom D.; Secosky-Chang M.B.; Tomaszek T.; McConn D.; Wells-Knecht K.; Johnson P.R.; 2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV. Bioorg Med Chem Lett 2005,15(23),5257-5261","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.bmcl.2005.03.077","volume":"15","author":"Sakashita H.","year":"2005","unstructured":"Sakashita H.; Kitajima H.; Nakamura M.; Akahoshi F.; Hayashi Y.; 1-((S)-&#x3B3;-substituted prolyl)-(S)-2-cyanopyrro-lidine as a novel series of highly potent DPP-IV inhibitors. Bioorg Med Chem Lett 2005,15(10),2441-2445","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1021\/jm0600085","volume":"49","author":"Wright S.W.","year":"2006","unstructured":"Wright S.W.; Ammirati M.J.; Andrews K.M.; Brodeur A.M.; Danley D.E.; Doran S.D.; Lillquist J.S.; McClure L.D.; McPherson R.K.; Orena S.J.; Parker J.C.; Polivkova J.; Qiu X.; Soeller W.C.; Soglia C.B.; Treadway J.L.; VanVolkenburg M.A.; Wang H.; Wilder D.C.; Olson T.V.; Cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization. J Med Chem 2006,49(11),3068-3076","journal-title":"J Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.bmcl.2006.12.019","volume":"17","author":"Coumar M.S.","year":"2007","unstructured":"Coumar M.S.; Chang C.N.; Chen C.T.; Chen X.; Chien C.H.; Tsai T.Y.; Cheng J.H.; Wu H.Y.; Han C.H.; Wu S.H.; Huang Y.W.; Hsu T.; Hsu L.J.; Chao Y.S.; Hsieh H.P.; Jiaang W.T.; 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. Bioorg Med Chem Lett 2007,17(5),1274-1279","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1016\/j.bmcl.2007.10.063","volume":"17","author":"Corbett J.W.","year":"2007","unstructured":"Corbett J.W.; Dirico K.; Song W.; Boscoe B.P.; Doran S.D.; Boyer D.; Qiu X.; Ammirati M.; Vanvolkenburg M.A.; McPherson R.K.; Parker J.C.; Cox E.D.; Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. Bioorg Med Chem Lett 2007,17(24),6707-6713","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1016\/j.bmc.2008.01.016","volume":"16","author":"Fukushima H.","year":"2008","unstructured":"Fukushima H.; Hiratate A.; Takahashi M.; Mikami A.; Saito-Hori M.; Munetomo E.; Kitano K.; Chonan S.; Saito H.; Suzuki A.; Takaoka Y.; Yamamoto K.; Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem 2008,16(7),4093-4106","journal-title":"Bioorg Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"7221","DOI":"10.1016\/j.bmc.2011.09.043","volume":"19","author":"Kato N.","year":"2011","unstructured":"Kato N.; Oka M.; Murase T.; Yoshida M.; Sakairi M.; Yamashita S.; Yasuda Y.; Yoshikawa A.; Hayashi Y.; Makino M.; Takeda M.; Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl} amino)-2-methylpropyl]-2-methylpyrazolo [1, 5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011,19(23),7221-7227","journal-title":"Bioorg Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.bmcl.2013.01.104","volume":"23","author":"Zhao G.","year":"2013","unstructured":"Zhao G.; Kwon C.; Wang A.; Robertson J.G.; Marcinkeviciene J.; Parker R.A.; Kirby M.S.; Hamann L.G.; Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2013,23(6),1622-1625","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1016\/j.bmc.2018.07.018","volume":"26","author":"Kuranov S.O.","year":"2018","unstructured":"Kuranov S.O.; Tsypysheva I.P.; Khvostov M.V.; Zainullina L.F.; Borisevich S.S.; Vakhitova Y.V.; Luzina O.A.; Salakhutdinov N.F.; Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 2018,26(15),4402-4409","journal-title":"Bioorg Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bmcl.2003.12.040","volume":"14","author":"Caldwell C.G.","year":"2004","unstructured":"Caldwell C.G.; Chen P.; He J.; Parmee E.R.; Leiting B.; Marsilio F.; Patel R.A.; Wu J.K.; Eiermann G.J.; Petrov A.; He H.; Lyons K.A.; Thornberry N.A.; Weber A.E.; Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004,14(5),1265-1268","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1016\/j.bmcl.2005.07.026","volume":"15","author":"Hulin B.","year":"2005","unstructured":"Hulin B.; Cabral S.; Lopaze M.G.; Van Volkenburg M.A.; Andrews K.M.; Parker J.C.; New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2005,15(21),4770-4773","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1016\/j.bmcl.2010.04.124","volume":"20","author":"Yeh T.K.","year":"2010","unstructured":"Yeh T.K.; Tsai T.Y.; Hsu T.; Cheng J.H.; Chen X.; Song J.S.; Shy H.S.; Chiou M.C.; Chien C.H.; Tseng Y.J.; Huang C.Y.; Yeh K.C.; Huang Y.L.; Huang C.H.; Huang Y.W.; Wang M.H.; Tang H.K.; Chao Y.S.; Chen C.T.; Jiaang W.T.; (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. Bioorg Med Chem Lett 2010,20(12),3596-3600","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejphar.2011.01.010","volume":"655","author":"Tajima A.","year":"2011","unstructured":"Tajima A.; Yamamoto K.; Kozakai A.; Okumura-Kitajima L.; Mita Y.; Kitano K.; Jingu S.; Nakaike S.; (2S,4S)-4-Fluoro-1-[(2-hydroxy-1,1-dimethylethyl)amino]acetyl-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor. Eur J Pharmacol 2011,655(1-3),99-107","journal-title":"Eur J Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/cbdd.12142","volume":"82","author":"Sharma M.","year":"2013","unstructured":"Sharma M.; Gupta M.; Singh D.; Kumar M.; Kaur P.; Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors. Chem Biol Drug Des 2013,82(2),156-166","journal-title":"Chem Biol Drug Des"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1016\/j.bmcl.2004.08.057","volume":"14","author":"Ferraris D.","year":"2004","unstructured":"Ferraris D.; Ko Y.S.; Calvin D.; Chiou T.; Lautar S.; Thomas B.; Wozniak K.; Rojas C.; Kalish V.; Belyakov S.; Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors. Bioorg Med Chem Lett 2004,14(22),5579-5583","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0968-0896(02)00384-X","volume":"11","author":"Zhao K.","year":"2003","unstructured":"Zhao K.; Lim D.S.; Funaki T.; Welch J.T.; Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg Med Chem 2003,11(2),207-215","journal-title":"Bioorg Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1021\/jm0495982","volume":"48","author":"Van der Veken P.","year":"2005","unstructured":"Van der Veken P.; Senten K.; Kert&#xE8;sz I.; De Meester I.; Lambeir A.M.; Maes M.B.; Scharp&#xE9; S.; Haemers A.; Augustyns K.; Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases. J Med Chem 2005,48(6),1768-1780","journal-title":"J Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.bmcl.2008.02.050","volume":"18","author":"Edmondson S.D.","year":"2008","unstructured":"Edmondson S.D.; Wei L.; Xu J.; Shang J.; Xu S.; Pang J.; Chaudhary A.; Dean D.C.; He H.; Leiting B.; Lyons K.A.; Patel R.A.; Patel S.B.; Scapin G.; Wu J.K.; Beconi M.G.; Thornberry N.A.; Weber A.E.; Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2008,18(7),2409-2413","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1016\/j.bmcl.2004.07.056","volume":"14","author":"Edmondson S.D.","year":"2004","unstructured":"Edmondson S.D.; Mastracchio A.; Beconi M.; Colwell L.F.; Habulihaz B.; He H.; Kumar S.; Leiting B.; Lyons K.A.; Mao A.; Marsilio F.; Patel R.A.; Wu J.K.; Zhu L.; Thornberry N.A.; Weber A.E.; Parmee E.R.; Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004,14(20),5151-5155","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.bmcl.2007.01.026","volume":"17","author":"Backes B.J.","year":"2007","unstructured":"Backes B.J.; Longenecker K.; Hamilton G.L.; Stewart K.; Lai C.; Kopecka H.; von Geldern T.W.; Madar D.J.; Pei Z.; Lubben T.H.; Zinker B.A.; Tian Z.; Ballaron S.J.; Stashko M.A.; Mika A.K.; Beno D.W.; Kempf-Grote A.J.; Black-Schaefer C.; Sham H.L.; Trevillyan J.M.; Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. Bioorg Med Chem Lett 2007,17(7),2005-2012","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.bmc.2007.11.031","volume":"16","author":"Kondo T.","year":"2008","unstructured":"Kondo T.; Nekado T.; Sugimoto I.; Ochi K.; Takai S.; Kinoshita A.; Hatayama A.; Yamamoto S.; Kishikawa K.; Nakai H.; Toda M.; Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem 2008,16(4),1613-1631","journal-title":"Bioorg Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.bmcl.2011.01.055","volume":"21","author":"Andrews K.M.","year":"2011","unstructured":"Andrews K.M.; Beebe D.A.; Benbow J.W.; Boyer D.A.; Doran S.D.; Hui Y.; Liu S.; McPherson R.K.; Neagu C.; Parker J.C.; Piotrowski D.W.; Schneider S.R.; Treadway J.L.; VanVolkenberg M.A.; Zembrowski W.J.; 1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2011,21(6),1810-1814","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ardp.201500082","volume":"348","author":"Jiang T.","year":"2015","unstructured":"Jiang T.; Zhou Y.; Zhu J.; Chen Z.; Sun P.; Zhang Q.; Wang Z.; Shao Q.; Jiang X.; Li B.; Wang H.; Zhu W.; Shen J.; Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors. Arch Pharm (Weinheim) 2015,348(6),399-407","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.bmcl.2016.04.020","volume":"26","author":"Cox J.M.","year":"2016","unstructured":"Cox J.M.; Chu H.D.; Kuethe J.T.; Gao Y.D.; Scapin G.; Eiermann G.; He H.; Li X.; Lyons K.A.; Metzger J.; Petrov A.; Wu J.K.; Xu S.; Sinha-Roy R.; Weber A.E.; Biftu T.; The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors. Bioorg Med Chem Lett 2016,26(11),2622-2626","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1747-0285.2012.01365.x","volume":"79","author":"Wu D.","year":"2012","unstructured":"Wu D.; Jin F.; Lu W.; Zhu J.; Li C.; Wang W.; Tang Y.; Jiang H.; Huang J.; Liu G.; Li J.; Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors. Chem Biol Drug Des 2012,79(6),897-906","journal-title":"Chem Biol Drug Des"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1016\/j.bmcl.2015.09.015","volume":"25","author":"Sagar S.R.","year":"2015","unstructured":"Sagar S.R.; Agarwal J.K.; Pandya D.H.; Dash R.P.; Nivsarkar M.; Vasu K.K.; Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes. Bioorg Med Chem Lett 2015,25(20),4428-4433","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=43","author":"Villhauer E.B.","year":"2000","unstructured":"Villhauer E.B.; Novartis A.G.N.N.; N-(Substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containingthem and their use in inhibiting dipeptidyl peptidase-IV. US Patent 6,110,949 2000","journal-title":"US Patent 6,110,949"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.bmcl.2011.01.041","volume":"21","author":"Park W.S.","year":"2011","unstructured":"Park W.S.; Kang S.K.; Jun M.A.; Shin M.S.; Kim K.Y.; Rhee S.D.; Bae M.A.; Kim M.S.; Kim K.R.; Kang N.S.; Yoo S.E.; Lee J.O.; Song D.H.; Silinski P.; Schneider S.E.; Ahn J.H.; Kim S.S.; Discovery of &#x3B2;-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2011,21(5),1366-1370","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1016\/j.bmc.2012.08.012","volume":"20","author":"Yoshida T.","year":"2012","unstructured":"Yoshida T.; Akahoshi F.; Sakashita H.; Kitajima H.; Nakamura M.; Sonda S.; Takeuchi M.; Tanaka Y.; Ueda N.; Sekiguchi S.; Ishige T.; Shima K.; Nabeno M.; Abe Y.; Anabuki J.; Soejima A.; Yoshida K.; Takashina Y.; Ishii S.; Kiuchi S.; Fukuda S.; Tsutsumiuchi R.; Kosaka K.; Murozono T.; Nakamaru Y.; Utsumi H.; Masutomi N.; Kishida H.; Miyaguchi I.; Hayashi Y.; Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem 2012,20(19),5705-5719","journal-title":"Bioorg Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1016\/j.bmc.2012.06.033","volume":"20","author":"Yoshida T.","year":"2012","unstructured":"Yoshida T.; Akahoshi F.; Sakashita H.; Sonda S.; Takeuchi M.; Tanaka Y.; Nabeno M.; Kishida H.; Miyaguchi I.; Hayashi Y.; Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem 2012,20(16),5033-5041","journal-title":"Bioorg Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1016\/j.bmcl.2004.06.099","volume":"14","author":"Xu J.","year":"2004","unstructured":"Xu J.; Ok H.O.; Gonzalez E.J.; Colwell L.F.; Habulihaz B.; He H.; Leiting B.; Lyons K.A.; Marsilio F.; Patel R.A.; Wu J.K.; Thornberry N.A.; Weber A.E.; Parmee E.R.; Discovery of potent and selective &#x3B2;-homophenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004,14(18),4759-4762","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1016\/j.bmcl.2012.09.099","volume":"22","author":"Nitta A.","year":"2012","unstructured":"Nitta A.; Fujii H.; Sakami S.; Satoh M.; Nakaki J.; Satoh S.; Kumagai H.; Kawai H.; Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2012,22(23),7036-7040","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=49","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201600298","volume":"350","author":"Ali Z.","year":"2017","unstructured":"Ali Z.; Akhtar M.J.; Siddiqui A.A.; Khan A.A.; Haider M.R.; Yar M.S.; Design, synthesis, and biological evaluation of novel quinazoline clubbed thiazoline derivatives. Arch Pharm (Weinheim) 2017,350(2)","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1016\/j.bmcl.2007.08.030","volume":"17","author":"Chen P.","year":"2007","unstructured":"Chen P.; Caldwell C.G.; Mathvink R.J.; Leiting B.; Marsilio F.; Patel R.A.; Wu J.K.; He H.; Lyons K.A.; Thornberry N.A.; Weber A.E.; Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Bioorg Med Chem Lett 2007,17(21),5853-5857","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.bmcl.2008.02.071","volume":"18","author":"Wallace M.B.","year":"2008","unstructured":"Wallace M.B.; Feng J.; Zhang Z.; Skene R.J.; Shi L.; Caster C.L.; Kassel D.B.; Xu R.; Gwaltney S.L.; II. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2008,18(7),2362-2367","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1016\/j.ejmech.2009.03.021","volume":"44","author":"Wang L.","year":"2009","unstructured":"Wang L.; Zhang B.; Ji J.; Li B.; Yan J.; Zhang W.; Wu Y.; Wang X.; Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2009,44(8),3318-3322","journal-title":"Eur J Med Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1016\/j.bmcl.2010.08.090","volume":"20","author":"O\u2019Connor S.P.","year":"2010","unstructured":"O\u2019Connor S.P.; Wang Y.; Simpkins L.M.; Brigance R.P.; Meng W.; Wang A.; Kirby M.S.; Weigelt C.A.; Hamann L.G.; Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors. Bioorg Med Chem Lett 2010,20(21),6273-6276","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1016\/j.bmc.2012.07.046","volume":"20","author":"Ikuma Y.","year":"2012","unstructured":"Ikuma Y.; Hochigai H.; Kimura H.; Nunami N.; Kobayashi T.; Uchiyama K.; Furuta Y.; Sakai M.; Horiguchi M.; Masui Y.; Okazaki K.; Sato Y.; Nakahira H.; Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorg Med Chem 2012,20(19),5864-5883","journal-title":"Bioorg Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/cbdd.12560","volume":"86","author":"Li Q.","year":"2015","unstructured":"Li Q.; Zhou M.; Han L.; Cao Q.; Wang X.; Zhao L.; Zhou J.; Zhang H.; Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. Chem Biol Drug Des 2015,86(4),849-856","journal-title":"Chem Biol Drug Des"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1080\/00397911.2018.1508723","volume":"48","author":"Karandikar S.","year":"2018","unstructured":"Karandikar S.; Soni R.; Soman S.S.; Umar S.; Suresh B.; 1, 2-Benzisoxazole-3-acetamide derivatives as dual agents for DPP-IV inhibition and anticancer activity. Synth Commun 2018,48(22),2877-2887","journal-title":"Synth Commun"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1016\/j.bmcl.2007.04.106","volume":"17","author":"Gao Y.D.","year":"2007","unstructured":"Gao Y.D.; Feng D.; Sheridan R.P.; Scapin G.; Patel S.B.; Wu J.K.; Zhang X.; Sinha-Roy R.; Thornberry N.A.; Weber A.E.; Biftu T.; Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorg Med Chem Lett 2007,17(14),3877-3879","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1016\/j.bmcl.2011.09.074","volume":"21","author":"Wang W.","year":"2011","unstructured":"Wang W.; Devasthale P.; Wang A.; Harrity T.; Egan D.; Morgan N.; Cap M.; Fura A.; Klei H.E.; Kish K.; Weigelt C.; Sun L.; Levesque P.; Li Y.X.; Zahler R.; Kirby M.S.; Hamann L.G.; 7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site. Bioorg Med Chem Lett 2011,21(22),6646-6651","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejmech.2012.03.015","volume":"52","author":"Xie H.","year":"2012","unstructured":"Xie H.; Zeng L.; Zeng S.; Lu X.; Zhang G.; Zhao X.; Cheng N.; Tu Z.; Li Z.; Xu H.; Yang L.; Zhang X.; Huang M.; Zhao J.; Hu W.; Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. Eur J Med Chem 2012,52,205-212","journal-title":"Eur J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1021\/jm0493156","volume":"48","author":"Kim D.","year":"2005","unstructured":"Kim D.; Wang L.; Beconi M.; Eiermann G.J.; Fisher M.H.; He H.; Hickey G.J.; Kowalchick J.E.; Leiting B.; Lyons K.; Marsilio F.; McCann M.E.; Patel R.A.; Petrov A.; Scapin G.; Patel S.B.; Roy R.S.; Wu J.K.; Wyvratt M.J.; Zhang B.B.; Zhu L.; Thornberry N.A.; Weber A.E.; (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4] triazolo [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005,48(1),141-151","journal-title":"J Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1016\/j.bmcl.2007.07.100","volume":"17","author":"Kowalchick J.E.","year":"2007","unstructured":"Kowalchick J.E.; Leiting B.; Pryor K.D.; Marsilio F.; Wu J.K.; He H.; Lyons K.A.; Eiermann G.J.; Petrov A.; Scapin G.; Patel R.A.; Thornberry N.A.; Weber A.E.; Kim D.; Design, synthesis, and biological evaluation of triazolopiperazine-based &#x3B2;-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorg Med Chem Lett 2007,17(21),5934-5939","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/cbdd.12041","volume":"80","author":"Sharma M.","year":"2012","unstructured":"Sharma M.; Gupta M.; Singh D.; Kumar M.; Kaur P.; Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors. Chem Biol Drug Des 2012,80(6),918-928","journal-title":"Chem Biol Drug Des"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/cbdd.12593","volume":"86","author":"Gomha S.M.","year":"2015","unstructured":"Gomha S.M.; Eldebss T.M.; Badrey M.G.; Abdulla M.M.; Mayhoub A.S.; Novel 4-heteroaryl-antipyrines as DPP-IV inhibitors. Chem Biol Drug Des 2015,86(5),1292-1303","journal-title":"Chem Biol Drug Des"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1021\/ml500503n","volume":"6","author":"Schwehm C.","year":"2015","unstructured":"Schwehm C.; Li J.; Song H.; Hu X.; Kellam B.; Stocks M.J.; Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold. ACS Med Chem Lett 2015,6(3),324-328","journal-title":"ACS Med Chem Lett"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.bioorg.2017.10.010","volume":"75","author":"Deng X.","year":"2017","unstructured":"Deng X.; Han L.; Zhou J.; Zhang H.; Li Q.; Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. Bioorg Chem 2017,75,357-367","journal-title":"Bioorg Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"9598","DOI":"10.1039\/C6OB01818A","volume":"14","author":"Li Q.","year":"2016","unstructured":"Li Q.; Han L.; Zhang B.; Zhou J.; Zhang H.; Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors. Org Biomol Chem 2016,14(40),9598-9611","journal-title":"Org Biomol Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/jm101016w","volume":"54","author":"Zhang Z.","year":"2011","unstructured":"Zhang Z.; Wallace M.B.; Feng J.; Stafford J.A.; Skene R.J.; Shi L.; Lee B.; Aertgeerts K.; Jennings A.; Xu R.; Kassel D.B.; Kaldor S.W.; Navre M.; Webb D.R.; Gwaltney S.L.; Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J Med Chem 2011,54(2),510-524","journal-title":"J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1021\/jm100634a","volume":"53","author":"Meng W.","year":"2010","unstructured":"Meng W.; Brigance R.P.; Chao H.J.; Fura A.; Harrity T.; Marcinkeviciene J.; O\u2019Connor S.P.; Tamura J.K.; Xie D.; Zhang Y.; Klei H.E.; Kish K.; Weigelt C.A.; Turdi H.; Wang A.; Zahler R.; Kirby M.S.; Hamann L.G.; Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem 2010,53(15),5620-5628","journal-title":"J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1016\/j.bmc.2011.07.042","volume":"19","author":"Nishio Y.","year":"2011","unstructured":"Nishio Y.; Kimura H.; Sawada N.; Sugaru E.; Horiguchi M.; Ono M.; Furuta Y.; Sakai M.; Masui Y.; Otani M.; Hashizuka T.; Honda Y.; Deguchi J.; Nakagawa T.; Nakahira H.; 2-(6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-ylmethyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A. Bioorg Med Chem 2011,19(18),5490-5499","journal-title":"Bioorg Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejmech.2010.10.016","volume":"46","author":"Deng J.","year":"2011","unstructured":"Deng J.; Peng L.; Zhang G.; Lan X.; Li C.; Chen F.; Zhou Y.; Lin Z.; Chen L.; Dai R.; Xu H.; Yang L.; Zhang X.; Hu W.; The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. Eur J Med Chem 2011,46(1),71-76","journal-title":"Eur J Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900238","volume":"353","author":"Tomovic K.","year":"2020","unstructured":"Tomovic K.; Ilic B.S.; Miljkovic M.; Dimov S.; Yancheva D.; Kojic M.; Mavrova A.T.; Kocic G.; Smelcerovic A.; Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4. Arch Pharm (Weinheim) 2020,353(1)","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ejmech.2014.06.044","volume":"83","author":"Lai Z.W.","year":"2014","unstructured":"Lai Z.W.; Li C.; Liu J.; Kong L.; Wen X.; Sun H.; Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. Eur J Med Chem 2014,83,547-560","journal-title":"Eur J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molstruc.2018.01.014","volume":"1158","author":"Jha V.","year":"2018","unstructured":"Jha V.; Bhadoriya K.S.; Synthesis, pharmacological evaluation and molecular docking studies of pyrimidinedione based DPP-4 inhibitors as antidiabetic agents. J Mol Struct 2018,1158,96-105","journal-title":"J Mol Struct"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.bmc.2019.01.001","volume":"27","author":"Huang J.","year":"2019","unstructured":"Huang J.; Deng X.; Zhou S.; Wang N.; Qin Y.; Meng L.; Li G.; Xiong Y.; Fan Y.; Guo L.; Lan D.; Xing J.; Jiang W.; Li Q.; Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent dipeptidyl peptidase-IV inhibitors. Bioorg Med Chem 2019,27(4),644-654","journal-title":"Bioorg Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bmc.2010.11.038","volume":"19","author":"Miyamoto Y.","year":"2011","unstructured":"Miyamoto Y.; Banno Y.; Yamashita T.; Fujimoto T.; Oi S.; Moritoh Y.; Asakawa T.; Kataoka O.; Takeuchi K.; Suzuki N.; Ikedo K.; Kosaka T.; Tsubotani S.; Tani A.; Funami M.; Amano M.; Yamamoto Y.; Aertgeerts K.; Yano J.; Maezaki H.; Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorg Med Chem 2011,19(1),172-185","journal-title":"Bioorg Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/ml100200c","volume":"1","author":"Kaczanowska K.","year":"2010","unstructured":"Kaczanowska K.; Wiesm&#xFC;ller K.H.; Schaffner A.P.; Design, synthesis, and in vitro evaluation of novel aminomethyl-pyridines as DPP-4 inhibitors. ACS Med Chem Lett 2010,1(9),530-535","journal-title":"ACS Med Chem Lett"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1016\/j.bmcl.2004.04.049","volume":"14","author":"Peters J.U.","year":"2004","unstructured":"Peters J.U.; Weber S.; Kritter S.; Weiss P.; Wallier A.; Zimmerli D.; Boehringer M.; Steger M.; Loeffler B.M.; Aminomethylpyridines as DPP-IV inhibitors. Bioorg Med Chem Lett 2004,14(13),3579-3580","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.bmcl.2008.04.075","volume":"18","author":"Eckhardt M.","year":"2008","unstructured":"Eckhardt M.; Hauel N.; Himmelsbach F.; Langkopf E.; Nar H.; Mark M.; Tadayyon M.; Thomas L.; Guth B.; Lotz R.; 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg Med Chem Lett 2008,18(11),3158-3162","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.bmcl.2013.12.118","volume":"24","author":"Namoto K.","year":"2014","unstructured":"Namoto K.; Sirockin F.; Ostermann N.; Gessier F.; Flohr S.; Sedrani R.; Gerhartz B.; Trappe J.; Hassiepen U.; Duttaroy A.; Ferreira S.; Sutton J.M.; Clark D.E.; Fenton G.; Beswick M.; Baeschlin D.K.; Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 2014,24(3),731-736","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1016\/j.bmcl.2011.04.029","volume":"21","author":"Kim H.J.","year":"2011","unstructured":"Kim H.J.; Kwak W.Y.; Min J.P.; Lee J.Y.; Yoon T.H.; Kim H.D.; Shin C.Y.; Kim M.K.; Choi S.H.; Kim H.S.; Yang E.K.; Cheong Y.H.; Chae Y.N.; Park K.J.; Jang J.M.; Choi S.J.; Son M.H.; Kim S.H.; Yoo M.; Lee B.J.; Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2011,21(12),3809-3812","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cbdd.12426","volume":"85","author":"Kushwaha R.N.","year":"2015","unstructured":"Kushwaha R.N.; Srivastava R.; Mishra A.; Rawat A.K.; Srivastava A.K.; Haq W.; Katti S.B.; Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes. Chem Biol Drug Des 2015,85(4),439-446","journal-title":"Chem Biol Drug Des"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1016\/j.bmcl.2009.06.011","volume":"19","author":"Edmondson S.D.","year":"2009","unstructured":"Edmondson S.D.; Mastracchio A.; Cox J.M.; Eiermann G.J.; He H.; Lyons K.A.; Patel R.A.; Patel S.B.; Petrov A.; Scapin G.; Wu J.K.; Xu S.; Zhu B.; Thornberry N.A.; Roy R.S.; Weber A.E.; Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg Med Chem Lett 2009,19(15),4097-4101","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1016\/j.bmcl.2009.07.058","volume":"19","author":"Gupta R.C.","year":"2009","unstructured":"Gupta R.C.; Chhipa L.; Mandhare A.B.; Zambad S.P.; Chauthaiwale V.; Nadkarni S.S.; Dutt C.; Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. Bioorg Med Chem Lett 2009,19(17),5021-5025","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.bmcl.2009.02.099","volume":"19","author":"Benbow J.W.","year":"2009","unstructured":"Benbow J.W.; Andrews K.A.; Aubrecht J.; Beebe D.; Boyer D.; Doran S.; Homiski M.; Hui Y.; McPherson K.; Parker J.C.; Treadway J.; Vanvolkenberg M.; Zembrowski W.J.; Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2009,19(8),2220-2223","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1016\/j.bmcl.2010.10.101","volume":"20","author":"Nishio Y.","year":"2010","unstructured":"Nishio Y.; Kimura H.; Tosaki S.; Sugaru E.; Sakai M.; Horiguchi M.; Masui Y.; Ono M.; Nakagawa T.; Nakahira H.; Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore. Bioorg Med Chem Lett 2010,20(24),7246-7249","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.bmcl.2010.12.060","volume":"21","author":"Chen P.","year":"2011","unstructured":"Chen P.; Caldwell C.G.; Ashton W.; Wu J.K.; He H.; Lyons K.A.; Thornberry N.A.; Weber A.E.; Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors. Bioorg Med Chem Lett 2011,21(6),1880-1886","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/cbdd.12327","volume":"84","author":"Xing J.","year":"2014","unstructured":"Xing J.; Li Q.; Zhang S.; Liu H.; Zhao L.; Cheng H.; Zhang Y.; Zhou J.; Zhang H.; Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation. Chem Biol Drug Des 2014,84(3),364-377","journal-title":"Chem Biol Drug Des"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.bmcl.2014.03.009","volume":"24","author":"Jadav P.","year":"2014","unstructured":"Jadav P.; Bahekar R.; Shah S.R.; Patel D.; Joharapurkar A.; Jain M.; Sairam K.V.; Singh P.K.; Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors. Bioorg Med Chem Lett 2014,24(8),1918-1922","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/cbdd.12663","volume":"87","author":"Ran Y.","year":"2016","unstructured":"Ran Y.; Pei H.; Shao M.; Chen L.; Synthesis, biological evaluation, and molecular docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as dipeptidyl peptidase IV inhibitors. Chem Biol Drug Des 2016,87(2),290-295","journal-title":"Chem Biol Drug Des"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"14095","DOI":"10.1039\/C4RA16903D","volume":"5","author":"Srivastava J.K.","year":"2015","unstructured":"Srivastava J.K.; Dubey P.; Singh S.; Bhat H.R.; Kumawat M.K.; Singh U.P.; Discovery of novel 1, 3, 5-triazine-thiazolidine-2, 4-diones as dipeptidyl peptidase-4 inhibitors with antibacterial activity targeting the S1 pocket for the treatment of type 2 diabetes. RSC Advances 2015,5(19),14095-14102","journal-title":"RSC Advances"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000494060","volume":"103","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; Tang X.; Yi L.; Design and discovery of novel 1,3,5-triazines as dipeptidyl peptidase-4 inhibitor against diabetes. Pharmacology 2019,103(5-6),273-281","journal-title":"Pharmacology"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bioorg.2017.03.004","volume":"72","author":"Patel B.D.","year":"2017","unstructured":"Patel B.D.; Bhadada S.V.; Ghate M.D.; Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors. Bioorg Chem 2017,72,345-358","journal-title":"Bioorg Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.bmcl.2007.01.111","volume":"17","author":"Ahn J.H.","year":"2007","unstructured":"Ahn J.H.; Shin M.S.; Jun M.A.; Jung S.H.; Kang S.K.; Kim K.R.; Rhee S.D.; Kang N.S.; Kim S.Y.; Sohn S.K.; Kim S.G.; Jin M.S.; Lee J.O.; Cheon H.G.; Kim S.S.; Synthesis, biological evaluation and structural determination of &#x3B2;-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg Med Chem Lett 2007,17(9),2622-2628","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1016\/j.bmcl.2013.07.061","volume":"23","author":"Biftu T.","year":"2013","unstructured":"Biftu T.; Qian X.; Chen P.; Feng D.; Scapin G.; Gao Y.D.; Cox J.; Roy R.S.; Eiermann G.; He H.; Lyons K.; Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2R, 3S, 5R)-2-(2, 5-difluorophenyl)-5-[2-(methylsulfonyl)-2, 6-dihydropyrrolo [3, 4-c] pyrazol-5 (4H)-yl] tetrahydro-2H-pyran-3-amine (23). Bioorg Med Chem Lett 2013,23(19),5361-5366","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cclet.2011.12.007","volume":"23","author":"Han B.","year":"2012","unstructured":"Han B.; Liu J.L.; Huan Y.; Li P.; Wu Q.; Lin Z.Y.; Shen Z.F.; Huang H.H.; Design, synthesis and primary activity of thiomorpholine derivatives as DPP-IV inhibitors. Chin Chem Lett 2012,23(3),297-300","journal-title":"Chin Chem Lett"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.bmcl.2004.11.023","volume":"15","author":"Jiaang W.T.","year":"2005","unstructured":"Jiaang W.T.; Chen Y.S.; Hsu T.; Wu S.H.; Chien C.H.; Chang C.N.; Chang S.P.; Lee S.J.; Chen X.; Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett 2005,15(3),687-691","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2191-2858-1-7","volume":"1","author":"Kato N.","year":"2011","unstructured":"Kato N.; Oka M.; Murase T.; Yoshida M.; Sakairi M.; Yakufu M.; Yamashita S.; Yasuda Y.; Yoshikawa A.; Hayashi Y.; Shirai M.; Mizuno Y.; Takeuchi M.; Makino M.; Takeda M.; Kakigami T.; Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors. Org Med Chem Lett 2011,1(1),7","journal-title":"Org Med Chem Lett"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cclet.2014.03.047","volume":"25","author":"Xiao P.F.","year":"2014","unstructured":"Xiao P.F.; Guo R.; Huang S.Q.; Cui H.J.; Ye S.; Zhang Z.; Discovery of dipeptidyl peptidase IV (DPP4) inhibitors based on a novel indole scaffold. Chin Chem Lett 2014,25(5),673-676","journal-title":"Chin Chem Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"6684","DOI":"10.1016\/j.bmc.2014.09.051","volume":"22","author":"Wang S.","year":"2014","unstructured":"Wang S.; Su M.; Wang J.; Li Z.; Zhang L.; Ji X.; Li J.; Li J.; Liu H.; (R)-3-amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: design, synthesis, biological evaluation, and molecular modeling. Bioorg Med Chem 2014,22(23),6684-6693","journal-title":"Bioorg Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1016\/j.bmcl.2007.03.072","volume":"17","author":"L&#xFC;bbers T.","year":"2007","unstructured":"L&#xFC;bbers T.; B&#xF6;hringer M.; Gobbi L.; Hennig M.; Hunziker D.; Kuhn B.; L&#xF6;ffler B.; Mattei P.; Narquizian R.; Peters J.U.; Ruff Y.; Wessel H.P.; Wyss P.; 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007,17(11),2966-2970","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bmcl.2009.12.025","volume":"20","author":"Boehringer M.","year":"2010","unstructured":"Boehringer M.; Fischer H.; Hennig M.; Hunziker D.; Huwyler J.; Kuhn B.; Loeffler B.M.; Luebbers T.; Mattei P.; Narquizian R.; Sebokova E.; Sprecher U.; Wessel H.P.; Aryl- and heteroaryl-substituted aminobenzo[a] quinolizines as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2010,20(3),1106-1108","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/jm070104l","volume":"50","author":"Feng J.","year":"2007","unstructured":"Feng J.; Zhang Z.; Wallace M.B.; Stafford J.A.; Kaldor S.W.; Kassel D.B.; Navre M.; Shi L.; Skene R.J.; Asakawa T.; Takeuchi K.; Xu R.; Webb D.R.; Gwaltney S.L.; Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007,50(10),2297-2300","journal-title":"J Med Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bioorg.2017.02.004","volume":"71","author":"Ali Z.","year":"2017","unstructured":"Ali Z.; Akhtar M.J.; Haider M.R.; Khan A.A.; Siddiqui A.A.; Yar M.S.; Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor. Bioorg Chem 2017,71,181-191","journal-title":"Bioorg Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/S0960-894X(00)00286-9","volume":"10","author":"Coppola G.M.","year":"2000","unstructured":"Coppola G.M.; Zhang Y.L.; Schuster H.F.; Russell M.E.; Hughes T.E.; 1-aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors. Bioorg Med Chem Lett 2000,10(14),1555-1558","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.bmc.2011.06.059","volume":"19","author":"Banno Y.","year":"2011","unstructured":"Banno Y.; Miyamoto Y.; Sasaki M.; Oi S.; Asakawa T.; Kataoka O.; Takeuchi K.; Suzuki N.; Ikedo K.; Kosaka T.; Tsubotani S.; Tani A.; Funami M.; Tawada M.; Yamamoto Y.; Aertgeerts K.; Yano J.; Maezaki H.; Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554. Bioorg Med Chem 2011,19(16),4953-4970","journal-title":"Bioorg Med Chem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.bmcl.2011.11.054","volume":"22","author":"Sutton J.M.","year":"2012","unstructured":"Sutton J.M.; Clark D.E.; Dunsdon S.J.; Fenton G.; Fillmore A.; Harris N.V.; Higgs C.; Hurley C.A.; Krintel S.L.; MacKenzie R.E.; Duttaroy A.; Gangl E.; Maniara W.; Sedrani R.; Namoto K.; Ostermann N.; Gerhartz B.; Sirockin F.; Trappe J.; Hassiepen U.; Baeschlin D.K.; Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2012,22(3),1464-1468","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1248\/cpb.c12-01046","volume":"61","author":"Lin K.","year":"2013","unstructured":"Lin K.; Cai Z.; Wang F.; Zhang W.; Zhou W.; Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4. Chem Pharm Bull (Tokyo) 2013,61(4),477-482","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.bmcl.2015.03.048","volume":"25","author":"Mo D.W.","year":"2015","unstructured":"Mo D.W.; Dong S.; Sun H.; Chen J.S.; Pang J.X.; Xi B.M.; Chen W.H.; Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro\/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg Med Chem Lett 2015,25(9),1872-1875","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejmech.2016.08.023","volume":"124","author":"Li G.","year":"2016","unstructured":"Li G.; Huan Y.; Yuan B.; Wang J.; Jiang Q.; Lin Z.; Shen Z.; Huang H.; Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Eur J Med Chem 2016,124,103-116","journal-title":"Eur J Med Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bioorg.2018.05.008","volume":"79","author":"Soni R.","year":"2018","unstructured":"Soni R.; Soman S.S.; Design and synthesis of aminocoumarin derivatives as DPP-IV inhibitors and anticancer agents. Bioorg Chem 2018,79,277-284","journal-title":"Bioorg Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1021\/acs.jmedchem.6b00505","volume":"59","author":"Li S.","year":"2016","unstructured":"Li S.; Xu H.; Cui S.; Wu F.; Zhang Y.; Su M.; Gong Y.; Qiu S.; Jiao Q.; Qin C.; Shan J.; Zhang M.; Wang J.; Yin Q.; Xu M.; Liu X.; Wang R.; Zhu L.; Li J.; Xu Y.; Jiang H.; Zhao Z.; Li J.; Li H.; Discovery and rational design of natural-product-derived 2-phenyl-3, 4-dihydro-2 H-benzo [f] chromen-3-amine analogs as novel and potent dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes. J Med Chem 2016,59(14),6772-6790","journal-title":"J Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1139\/cjc-2015-0039","volume":"93","author":"Abu Khalaf R.","year":"2015","unstructured":"Abu Khalaf R.; Jarekji Z.; Al-Qirim T.; Sabbah D.; Shattat G.; Pharmacophore modeling and molecular docking studies of acridines as potential DPP-IV inhibitors. Can J Chem 2015,93(7),721-729","journal-title":"Can J Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jfluchem.2009.08.001","volume":"130","author":"Park W.S.","year":"2009","unstructured":"Park W.S.; Jun M.A.; Shin M.S.; Kwon S.W.; Kang S.K.; Kim K.Y.; Dal Rhee S.; Bae M.A.; Narsaiah B.; Lee D.H.; Cheon H.G.; Synthesis and biological evaluation of triazepane derivatives as DPP-IV inhibitors. J Fluor Chem 2009,130(11),1001-1010","journal-title":"J Fluor Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ddr.20278","volume":"69","author":"Tsai H.J.","year":"2008","unstructured":"Tsai H.J.; Chou S.Y.; Chuang S.H.; Chen C.C.; Hsu F.L.; D\u2010420720, A novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor: structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition. Drug Dev Res 2008,69(8),514-519","journal-title":"Drug Dev Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ejmech.2014.11.041","volume":"90","author":"Sharma R.","year":"2015","unstructured":"Sharma R.; Soman S.S.; Design and synthesis of sulfonamide derivatives of pyrrolidine and piperidine as anti-diabetic agents. Eur J Med Chem 2015,90,342-350","journal-title":"Eur J Med Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"83438","DOI":"10.1039\/C6RA15948F","volume":"6","author":"Gao H.D.","year":"2016","unstructured":"Gao H.D.; Liu P.; Yang Y.; Gao F.; Sulfonamide-1, 3, 5-triazine\u2013thiazoles: discovery of a novel class of antidiabetic agents via inhibition of DPP-4. RSC Advances 2016,6(86),83438-83447","journal-title":"RSC Advances"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2174\/1573409914666180308164013","volume":"14","author":"Khalaf R.A.","year":"2018","unstructured":"Khalaf R.A.; Sabbah D.; Al-Shalabi E.; Al-Sheikh I.; Albadawi G.; Abu Sheikha G.; Synthesis, structural characterization and docking studies of sulfamoyl- phenyl acid esters as dipeptidyl peptidase-iv inhibitors. Curr Comput Aided Drug Des 2018,14(2),142-151","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.bioorg.2018.09.021","volume":"81","author":"Abd El-Karim S.S.","year":"2018","unstructured":"Abd El-Karim S.S.; Anwar M.M.; Syam Y.M.; Nael M.A.; Ali H.F.; Motaleb M.A.; Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D","journal-title":"Bioorg Chem"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1016\/j.bmcl.2009.05.109","volume":"19","author":"Nordhoff S.","year":"2009","unstructured":"Nordhoff S.; Cerezo-G&#xE1;lvez S.; Deppe H.; Hill O.; L&#xF3;pez-Canet M.; Rummey C.; Thiemann M.; Matassa V.G.; Edwards P.J.; Feurer A.; Discovery of &#x3B2;-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 2009,19(15),4201-4203","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1016\/j.bmc.2013.07.034","volume":"21","author":"Liu Y.","year":"2013","unstructured":"Liu Y.; Si M.; Tang L.; Shangguan S.; Wu H.; Li J.; Wu P.; Ma X.; Liu T.; Hu Y.; Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors. Bioorg Med Chem 2013,21(18),5679-5687","journal-title":"Bioorg Med Chem"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/acsmedchemlett.5b00074","volume":"6","author":"Jiang T.","year":"2015","unstructured":"Jiang T.; Zhou Y.; Chen Z.; Sun P.; Zhu J.; Zhang Q.; Wang Z.; Shao Q.; Jiang X.; Li B.; Chen K.; Jiang H.; Wang H.; Zhu W.; Shen J.; Design, synthesis, and pharmacological evaluation of fused &#x3B2;-homophenylalanine derivatives as potent DPP-4 inhibitors. ACS Med Chem Lett 2015,6(5),602-606","journal-title":"ACS Med Chem Lett"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1021\/jm00049a016","volume":"37","author":"Boduszek B.","year":"1994","unstructured":"Boduszek B.; Oleksyszyn J.; Kam C.M.; Selzler J.; Smith R.E.; Powers J.C.; Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J Med Chem 1994,37(23),3969-3976","journal-title":"J Med Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1021\/jm981033g","volume":"42","author":"Belyaev A.","year":"1999","unstructured":"Belyaev A.; Zhang X.; Augustyns K.; Lambeir A.M.; De Meester I.; Vedernikova I.; Scharp&#xE9; S.; Haemers A.; Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J Med Chem 1999,42(6),1041-1052","journal-title":"J Med Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbrc.2006.06.113","volume":"347","author":"Gilmore B.F.","year":"2006","unstructured":"Gilmore B.F.; Carson L.; McShane L.L.; Quinn D.; Coulter W.A.; Walker B.; Synthesis, kinetic evaluation, and utilization of a biotinylated dipeptide proline diphenyl phosphonate for the disclosure of dipeptidyl peptidase IV-like serine proteases. Biochem Biophys Res Commun 2006,347(1),373-379","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666201012153255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186791\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666201012153255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T11:13:25Z","timestamp":1654427605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186791\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":124,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666201012153255","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}